Report on Patients with Non Transfusion-Dependent β-Thalassemia Major Being Treated with Hydroxyurea Attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013

References

• Ley TJ, Desimon J, Anagnou NP, et al. 5-Azacytidine selectively increases γ-globin synthesis in a patient with β+ thalassemia. N Engl J Med. 1982;307(24):1469–1475
   PubMed Web of Science ®Google Scholar
• Yavarian M, Karimi M, Bakker E, et al. Response to hydroxyurea treatment in Iranian transfusion-dependent β-thalassemia patients. Haematologica. 2004;89(10):1172–1178
   PubMed Web of Science ®Google Scholar
• Musallam K, Taher A, Cappellini M, Sankaran V. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. Blood. 2013;121(12):2199–2212
   PubMed Web of Science ®Google Scholar
• Hajjah FM, Pearson HA. Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J Pediatr. 1994;125(3):490–492
   Google Scholar
• Olivieri N. Reactivation of fetal hemoglobin in patients with β-thalassemia. Semin Hematol. 1996;33(1):24–42
   PubMed Web of Science ®Google Scholar
• Olivieri N, Rees D, Ginder G, et al. Treatment of thalassemia major with phenylbutyrate and hydroxyurea. Lancet. 1997;350(9076):491–492
   PubMed Web of Science ®Google Scholar
• Arruda VR, Lima CS, Saad ST, Costa FF. Successful use of hydroxyurea in β-thalassemia major. N Eng J Med. 1997;336(13):964
   PubMed Web of Science ®Google Scholar
• Saxon B, Rees D, Olivieri N. Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in β thalassaemia. Br J Haematol. 1998;101(3):416–419
   PubMed Web of Science ®Google Scholar
• Kosaryan M, Yoosefy G, Mahdavi M, et al. The effect of hydroxyurea in milder forms of thalassemia. J Mazandaran Univ Med Sci. 2000;9(25):30–38
   Google Scholar
• Tamaddoni A, Toobaii H, Javaheri A. Determination of effectiveness of hydroxyurea in intermedia thalassemia. Proceedings of the 7th International Conference in Thalassemia and Hemoglobinopathies, Bankok, Thailand, June 1999 (Abstract 367)
   Google Scholar
• Kosaryan M, Vahidshahi K, Karami H, Ehteshami S. The effect of hydroxyurea in thalassemia major and intermedia in Iranian patients. Pakistan J Med Sci. 2009;25(1):74–78
   Web of Science ®Google Scholar
• Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27(7):380–385
   PubMed Web of Science ®Google Scholar
• Karimi M, Borzouee M, Mehrabani A, Cohan N. Echocardiographic finding in β-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in β-thalassemia intermedia. Eur J Haematol. 2009;82(3):213–218
   PubMed Web of Science ®Google Scholar
• Karimi M. Hydroxyurea in the management of thalassemia intermedia. Proceedings of the 1st Pan-Middle Eastern Conference on Haemoglobinopathies, Damascus, Syria, 1-2 May 2009. Hemoglobin. 2009;33(Suppl 1):S177–S182
   PubMedGoogle Scholar
• Karimi M, Cohan N, Moosavizadeh K, et al. Adverse effects of hydroxyurea in β-thalassemia intermedia patients: 10 years’ experience. Pediatr Hematol Oncol. 2010;27(3):205–211
   PubMed Web of Science ®Google Scholar
• Hashemisoteh M, Akhavan-Niaki H, Kosaryan M, et al. The role of β gene mutations in response to hydroxyurea therapy in patients with β thalassemia patients. J Mazandaran Univ Med Sci. 2008;18(64):1–10
   Google Scholar
• www.FDA.gov
   Google Scholar
• Koren A, Levin C, Dgany O, et al. Response to hydroxyurea therapy in β thalassemia. Am J Hematol. 2008;83(5):366–370
   PubMed Web of Science ®Google Scholar
• Bradai M, Pissard S, Abad MT, et al. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion. 2007;47(10):1830–1836
   PubMed Web of Science ®Google Scholar
• Karimi M, Haghpanah S, Farhadi A, Yavarian M. Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. Int J Hematol. 2012;95(1):51–56
   PubMed Web of Science ®Google Scholar
• Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27(7):380–385
   PubMed Web of Science ®Google Scholar
• Kosaryan M, Mojtahedzadeh F, Akhavan-Niaki H. The relationship of Xmn1 genotype with response to hydroxyurea in β thalassemia. Proceedings of the 9th International Conference in Thalassemia and Hemoglobinopathies held in Palermo, Italy, October 15-19 2003 (Poster 7)
   Google Scholar
• Ehsani M, Hedayati-Asl A, Bagheri A, et al. Hydroxyurea induced hematological response in transfusion-independent β-thalassemia intermedia: case series and review of literature. Pediatr Hematol Oncol. 2009;26(8):560–565
   PubMed Web of Science ®Google Scholar
• Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P. Hydroxyurea in the treatment of major β-thalassemia and importance of genetic screening. Ann Hematol. 2004;83(7):430–433
   PubMed Web of Science ®Google Scholar
• Karami H, Vahidshahi K, Kosaryan M, et al. Relationship between use of hydroxyurea and cholelithiasis in patients with major and intermediate β-thalassemia. J Mazandaran Univ Med Sci. 2007;17(61):62–68 [abstract in English]
   Google Scholar
• Mojtahedzadeh F, Kosaryan M, Kowsarian S, Karami H. Effect of hydroxyurea on extramedullary hematopoiesis masses in patients with β thalassemia intermedia. J Pejohandeh (Med J Shahid Beheshti Univ). 2008;13(2):81–88
   Google Scholar
• Rashidy-Ghader F, Kosaryan M. Cardiologic evaluation of thalassemic patients while using hydroxyurea. J Mazandaran Univ Med Sci. 2006;16(51):37–42 [abstract in English]
   Google Scholar
• Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332(20):1317–1322
   PubMed Web of Science ®Google Scholar
• Lanzkron S, Strouse JJ, Wilson R, et al. Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Int Med. 2008;148(12):939–956
   PubMed Web of Science ®Google Scholar